title: Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
abstract: Development of multidrug-resistance (MDR) remains a major cause of failure in the treatment of cancer with chemotherapeutic agents. In our efforts to explore alternative treatment regimens for multidrug-resistant tumors we have examined the sensitivity of MDR tumor cell lines to lymphokine activated killer (LAK) cells. Adriamycin (ADM) resistant B16-BL6 melanoma, L1210 and P388 leukemic cell lines were tested for sensitivity to lysis by LAK cells in vitro. While ADM-resistant B16-BL6 and L1210 sublines were found to exhibit at least 2-fold greater susceptibility to lysis by LAK cells, sensitivity of ADM-resistant P388 cell was similar to that of parental cells. Since ADM-resistant B16-BL6 cells were efficiently lysed by LAK cells in vitro, the efficacy of therapy with LAK cells against the ADM-resistant B16-BL6 subline in vivo was evaluated. Compared to mice bearing parental B16-BL6 tumor cells, the adoptive transfer of LAK cells and rIL2 significantly reduced formation of experimental metastases (P less than 0.009) and extended median survival time (P less than 0.001) of mice bearing ADM-resistant B16-BL6 tumor cells. Results suggest that immunotherapy with LAK cells and rIL2 may be a useful modality in the treatment of cancers with the MDR phenotype.
authors.affiliation: Research Institute, Cleveland Clinic Foundation, OH 44195.
authors.forename: S C
authors.initials: SC
authors.lastname: Gautam
authors.forename: N F
authors.initials: NF
authors.lastname: Chikkala
authors.forename: I
authors.initials: I
authors.lastname: Lewis
authors.forename: D R
authors.initials: DR
authors.lastname: Grabowski
authors.forename: J H
authors.initials: JH
authors.lastname: Finke
authors.forename: R
authors.initials: R
authors.lastname: Ganapathi
mesh_terms: D000818:Animals; D002999:Clone Cells; D003602:Cytotoxicity, Immunologic; D004317:Doxorubicin / Q000494:pharmacology*; D004351:Drug Resistance; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology* / Q000637:transplantation; D008175:Lung Neoplasms / Q000556:secondary* / Q000628:therapy; D008546:Melanoma, Experimental / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins; D004317:Doxorubicin